Highlights Depression and dementia are highly prevalent in older adults and often co-occur. Effectiveness of vortioxetine was assessed in patients
Abstract Background Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally evaluated
Abstract Background Analysis of efficacy and tolerability of vortioxetine 20 mg/day, and optimal timing of dose adjustment, in patients with major
Abstract Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and usually confer worse treatment outcomes. The long-term,
Highlights • About 50% of MDD patients treated with SSRIs or SNRIs suffer emotional blunting • Emotional blunting has important functional consequences for patients’ daily life
Abstract Purpose Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the patient.
Abstract Objective: To assess changes in workplace productivity and functioning in an open-label study in working patients receiving vortioxetine (10 to
Abstract Objective: To evaluate the consistency of vortioxetine's effects on functional capacity in adults with major depressive disorder (MDD) and
Abstract Objective: AtWoRC (Assessment in Work productivity and the Relationship with Cognitive symptoms) was an interventional, open-label, Canadian study (NCT02332954) designed
Abstract Background: This analysis investigates the efficacy of vortioxetine in adults with major depressive disorder (MDD) who report childhood or recent